Harvard Bioscience Inc
NASDAQ:HBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Harvard Bioscience Inc
NASDAQ:HBIO
|
US |
|
Xperi Holding Corp
LSE:0M2A
|
US |
|
P
|
Philippine Metals Inc
F:PM7A
|
CA |
|
I-nexus Global PLC
LSE:INX
|
UK |
|
Ricoh Co Ltd
TSE:7752
|
JP |
|
Italian Wine Brands S.P.A.
MIL:IWB
|
IT |
|
Farmers Edge Inc
TSX:FDGE
|
CA |
|
Next PLC
F:NXG0
|
UK |
|
Align Technology Inc
NASDAQ:ALGN
|
US |
|
V
|
Vikas Lifecare Ltd
NSE:VIKASLIFE
|
IN |
|
Mandarin Oriental International Ltd
OTC:MAORF
|
HK |
|
B
|
Barrick Gold Corp
XHAM:ABR
|
CA |
|
Churchill Capital Corp VII
NASDAQ:CVII
|
US |
|
Sunrise New Energy Co Ltd
NASDAQ:EPOW
|
CN |
|
B
|
Bradespar SA
XBER:FXMA
|
BR |
Wall St Price Targets
HBIO Price Targets Summary
Harvard Bioscience Inc
According to Wall Street analysts, the average 1-year price target for HBIO is 6.12 USD with a low forecast of 6.06 USD and a high forecast of 6.3 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HBIO's stock price target?
Price Target
6.12
USD
According to Wall Street analysts, the average 1-year price target for HBIO is 6.12 USD with a low forecast of 6.06 USD and a high forecast of 6.3 USD.
What is the Revenue forecast for Harvard Bioscience Inc?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been -2%. The projected CAGR for the next 2 years is 5%.
What is the Gross Profit forecast for Harvard Bioscience Inc?
Projected CAGR
8%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 0%. The projected CAGR for the next 2 years is 8%.
